Actuate Therapeutics
ACTU
43 hedge funds and large institutions have $80.5M invested in Actuate Therapeutics in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
17% more capital invested
Capital invested by funds: $68.5M → $80.5M (+$11.9M)
13% more funds holding
Funds holding: 38 → 43 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.43% less ownership
Funds ownership: 57.17% → 51.74% (-5.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$4.42M |
| 2 |
BlackRock
New York
|
+$628K |
| 3 |
BCM
BIOS Capital Management
Fort Worth,
Texas
|
+$616K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$374K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$198K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$206K |
| 2 |
NU
Northwestern University
Evanston,
Illinois
|
-$154K |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
-$79.7K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$75.5K |
| 5 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
-$68.4K |
ACTU Hedge Fund Activity: Q3 2025 in Review
43 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Actuate Therapeutics (ACTU) for Q3 2025, worth a combined $80.5M — up 17% from $68.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ACTU positions and 2 closed out — a net gain of 5 holders — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Voss Capital, adding an estimated $4.42M. The largest seller was Barclays, cutting an estimated $206K.
- 43 institutional investors held Actuate Therapeutics (ACTU) as of Q3 2025, up from 38 in Q2 2025.
- Funds reported $80.5M of Actuate Therapeutics stock for Q3 2025, up 17% quarter-over-quarter.
- 7 funds opened new Actuate Therapeutics positions in Q3 2025 and 2 closed out, a net change of +5 holders.
- The largest Actuate Therapeutics buyer in Q3 2025 was Voss Capital, an estimated $4.42M added.
- The largest Actuate Therapeutics seller in Q3 2025 was Barclays, an estimated $206K sold.
Based on aggregated 13F filings for Q3 2025.